TELO News & Events

Telomir Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has cleared the Company's Investigational New Drug, IND, application for its lead candidate, Telomir-Zn, for the treatment of patients with advanced or metastatic triple-negative breast cancer, TNBC.

Telomir Pharmaceuticals announced the successful closing of its previously announced acquisition of TELI Pharmaceuticals. The transaction, which was approved by Telomir's shareholders at the Company's Annual Meeting held on March 23, 2026, establishes Telomir as the sole holder of the global rights of Telomir-1.

elomir Pharmaceuticals announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for its lead candidate, Telomir-1, for the treatment of advanced and metastatic Triple-Negative Breast Cancer. The IND submission includes data from completed IND-enabling pharmacology, toxicology, and manufacturing studies. Subject to IND clearance, the Company plans to initiate a Phase 1/2 clinical trial evaluating Telomir-1 as an oral monotherapy in patients with advanced or metastatic TNBC. Subject to IND clearance, Telomir plans to initiate its Phase 1/2 clinical trial in advanced TNBC and continue advancing biomarker-driven development strategies. In parallel, the Company is continuing to expand its preclinical program, including evaluation of Telomir-Zn in additional TNBC animal models and further characterization of its mechanism of action. The Company has submitted scientific manuscripts to peer-reviewed journals and plans to present data at scientific conferences, including the AACR Annual Meeting 2026.

Telomir Pharmaceuticals announced new in vitro data demonstrating that Telomir-1 induces broad tumor cell mortality across biologically distinct subtypes of triple-negative breast cancer. Iron-rescue experiments confirmed that the observed tumor cell mortality is iron-dependent, directly supporting Telomir-Zn's proposed intracellular metal-modulating mechanism and distinguishing the effect from nonspecific cytotoxicity. Triple-negative breast cancer is an aggressive and molecularly heterogeneous disease lacking estrogen receptor, progesterone receptor and HER2 expression. Although chemotherapy, immunotherapy, PARP inhibitors, and antibody-drug conjugates have expanded available treatment options, outcomes in metastatic and treatment-resistant TNBC remain limited, and relapse rates remain high. Many TNBC tumors exhibit elevated intracellular iron levels and heightened oxidative stress, creating a biological reliance on redox-active metals to sustain proliferation and epigenetic modifications. Telomir-Zn is designed to modulate intracellular metal balance by reducing labile redox-active iron while increasing zinc availability. In the newly reported studies, tumor cell mortality observed across TNBC models was significantly attenuated when supplemental iron was introduced, confirming that the effect is mechanistically linked to disruption of tumor iron dependency. The study, conducted in collaboration with Pharmaseed, is evaluating five human TNBC cell lines representing distinct molecular subtypes. Three models have been completed to date: MDA-MB-468 - Near-complete tumor cell mortality at 72 hours HCC70 - Significant partial mortality MDA-MB-231 - Significant partial mortality Two additional models, BT-549 and HCC1806, are currently under evaluation. Across all completed models, supplemental iron significantly reduced Telomir-Zn-induced tumor cell death. The variability in magnitude of response across subtypes is consistent with the established biological heterogeneity of TNBC.